Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by Roth Mkm

Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by equities research analysts at Roth Mkm to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

Several other research analysts have also recently weighed in on ARCT. Citigroup cut their price objective on Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 6th. Wall Street Zen downgraded shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Wells Fargo & Company reduced their target price on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, October 23rd. Zacks Research cut shares of Arcturus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Finally, HC Wainwright lowered their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $34.00.

Arcturus Therapeutics Trading Down 0.8%

NASDAQ ARCT opened at $7.53 on Thursday. The business has a fifty day simple moving average of $6.81 and a 200 day simple moving average of $12.61. Arcturus Therapeutics has a 12 month low of $5.85 and a 12 month high of $24.17. The firm has a market capitalization of $213.93 million, a P/E ratio of -3.06 and a beta of 2.24.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. The firm had revenue of $17.15 million during the quarter, compared to analyst estimates of $17.47 million. As a group, sell-side analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

Several hedge funds have recently made changes to their positions in ARCT. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Arcturus Therapeutics by 4.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,026,588 shares of the biotechnology company’s stock valued at $12,423,000 after purchasing an additional 78,753 shares during the period. Hennion & Walsh Asset Management Inc. grew its holdings in Arcturus Therapeutics by 206.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 240,303 shares of the biotechnology company’s stock valued at $1,473,000 after buying an additional 161,910 shares in the last quarter. Byrne Asset Management LLC increased its position in shares of Arcturus Therapeutics by 4,412.5% during the fourth quarter. Byrne Asset Management LLC now owns 18,050 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 17,650 shares during the period. Green Alpha Advisors LLC lifted its holdings in shares of Arcturus Therapeutics by 31.9% in the fourth quarter. Green Alpha Advisors LLC now owns 28,282 shares of the biotechnology company’s stock worth $173,000 after buying an additional 6,839 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 27.5% in the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after acquiring an additional 1,567 shares during the period. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.